Celcuity (NASDAQ:CELC) Reaches New 12-Month High on Analyst Upgrade

Key Points

• Guggenheim upgraded Celcuity, raising its price target from $135 to $165 and keeping a buy rating, and the stock hit a new 52-week high, trading intraday as high as $142.50 (last around $140 vs prior close $125.65).
• Analyst coverage is skewed positive with 10 Buy, 1 Hold and 1 Sell ratings and a consensus price target of $125.40, yielding an overall "Moderate Buy" consensus despite the current share price exceeding that target.
• Insider Director Richard E. Buller sold 3,000 shares under a Rule 10b5-1 plan at $110.27, insiders own 13.33% while institutions own 63.33%; the company has a $6.9B market cap and reported Q1 EPS of -$0.97, beating estimates.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) reached a new 52-week high during mid-day trading on Monday after Guggenheim raised their price target on the stock from $135.00 to $165.00. Guggenheim currently has a buy rating on the stock. Celcuity traded as high as $142.50 and last traded at $140.0780, with a volume of 49816 shares traded. The stock had previously closed at $125.65.

CELC has been the subject of a number of other reports. Stifel Nicolaus set a $150.00 target price on shares of Celcuity in a research report on Monday. Citigroup reaffirmed an "outperform" rating on shares of Celcuity in a report on Monday. Wolfe Research reissued an "outperform" rating and set a $110.00 price objective on shares of Celcuity in a report on Thursday, March 12th. Citizens Jmp began coverage on Celcuity in a research report on Monday, April 27th. They issued a "market outperform" rating and a $150.00 target price for the company. Finally, Wall Street Zen lowered Celcuity from a "hold" rating to a "sell" rating in a research note on Saturday, April 25th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $125.40.

Insider Activity

In other news, Director Richard E. Buller sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total value of $330,810.00. Following the sale, the director owned 6,760 shares of the company's stock, valued at $745,425.20. The trade was a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Ogorek Anthony Joseph NY ADV lifted its position in shares of Celcuity by 19.7% during the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company's stock worth $66,000 after acquiring an additional 109 shares in the last quarter. US Bancorp DE grew its position in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company's stock valued at $35,000 after purchasing an additional 143 shares in the last quarter. Intech Investment Management LLC raised its stake in shares of Celcuity by 1.4% during the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company's stock valued at $1,295,000 after purchasing an additional 183 shares during the period. Aristides Capital LLC raised its stake in shares of Celcuity by 2.0% during the 4th quarter. Aristides Capital LLC now owns 15,303 shares of the company's stock valued at $1,526,000 after purchasing an additional 303 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock worth $34,000 after purchasing an additional 319 shares in the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Celcuity Price Performance

The business has a fifty day moving average of $114.53 and a 200-day moving average of $102.64. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20. The firm has a market cap of $6.90 billion, a PE ratio of -37.88 and a beta of 0.09.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.09. As a group, research analysts predict that Celcuity, Inc. will post -3.97 earnings per share for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.